Dasatinib improves outcomes in paediatric ALL
11 Apr 2020
byJairia Dela Cruz
Dasatinib outperforms imatinib in the treatment of Philadelphia chromosome–positive acute lymphoblastic leukaemia (ALL) in children, providing superior control of central nervous system (CNS) leukaemia without increasing toxicity and while doing away with prophylactic cranial irradiation, according to the results of the phase III CCCGALL-2015* trial.